John England, MD
Neurology · New Orleans, LANPI 1427169283
Payments from drug & device makers
Across 476 payments — averaging $563.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grifols USA, LLC$93K
- Argenx US, Inc.$83K
- Takeda Pharmaceuticals U.S.A., Inc.$55K
- Grifols Shared Services North America, Inc.$14K
- CSL Behring$13K
- Shire North American Group Inc$5K
- plus $7K from 34 others
What the payments were for
- Consulting fees$57,69221%
- Speaking & faculty fees$173,28965%
- Travel & lodging$27,13610%
- Food & beverage$10,1884%
- Education$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$268,347 in reported general payments places this provider in the 95th percentile of 225 neurology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 56 | $436,484 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 24 | $304,808 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 41 | $288,086 |
| GraliseGabapentin | 17 | $11,291 |
| Mycophenolate Mofetil | 34 | $2,636 |
| Gabapentin | 71 | $1,667 |
| Pregabalin | 40 | $873 |
| Prednisone | 42 | $222 |
| Duloxetine Hcl | 16 | $172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $12,593 | $436,48456 claims |
| Grifols USA, LLCGamunex-C | $92,763 | $304,80824 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $54,941 | $288,08641 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 225 neurology providers in Louisiana.
Other neurology in New Orleans
- Bridget BagertNew Orleans$1.4M
- Joseph TarsiaNew Orleans$1.2M
- Angela TraylorNew Orleans$941K
- Brian CopelandNew Orleans$304K
- Piotr OlejniczakNew Orleans$241K
- Sheryl Martin-SchildNew Orleans$106K
- Aimee AysenneNew Orleans$41K
- Caroline GoldinNew Orleans$38K
- Elizabeth CrabtreeNew Orleans$36K
- Jesus LoveraNew Orleans$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.